Europhartech

Own products (APIs) for the generic pharmaceutical industry.

We provide quality products and services, consistently,
reliably responsibly and continuously applying some of the world’s
most difficult to handle chemical technologies.
Our independent one-site,
single entity corporate setup enables


Synthesis: Manufacturing services and products for all user industries,
using Archimica´s highly differentiated setup and technologies
APIs, Building blocks, GMP intermediates, Regulatory Starting Materials
For all global markets including the United States of America,
in total Archimica products reach 25 countries.

Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.

What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.

How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.

Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.

Dossiers ready to file:
- Rasagiline (Parkinson’s diseases)
- Alprazolam (Anxiolytic)
- Deflazacort (Corticosteroid)
- Modafinil (Narcolepsy)
- Sildenafil (Erectil Dysfunction)
- Pioglitazone (Diabetes)
- Rivastigmine (Alzheimer diseases)

Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.

Please, contact us on generics@efarmes.es

Today's Euticals is one of the leading players in the pharmaceutical & fine chemicals industry with a global scale production and diversified manufacturing sites. All plants, located in Italy, France, Germany and USA are usually inspected by international and national regulatory agencies, such as FDA (acceptable with no 483), KFDA, ANVISA, etc.

Banking on, also, the last acquisitions, Poli-Industria Chimica in 2010 and Archimica in 2011, Euticals purpose is to be the ideal partner for pharmaceutical and chemical companies satisfying any inquiry, coming from the API generic market and pharmaceutical research companies, covering the worldwide area. The strategic proposition is to develop innovative solutions and ensure high quality and competitive prices by continuously improving every process and manufacturing activity.

Porton Biopharma Limited (PBL) is a UK based company experienced in developing and manufacturing biopharmaceutical therapeutics and vaccines.

PBL was corporatised out of Public Health England on 1st April 2015 to enable us to be better placed to grow our business, which is built upon decades of biopharmaceutical experience including the successful commercialisation and licensure of many therapies which now save thousands of lives every year, and generate revenues from world-wide sales.

Our strategy as an evolving company with a distinguished heritage is to grow and develop our existing business and products, whilst also building relationships across the industry.

As a growing company we are always looking to recruit talented individuals at all levels who have the drive and enthusiasm to help us get to where we want to be, and who are proud to be part of a team producing life-saving products that really make a difference.

Visit our website to find out more and see a complete list of our latest vacancies.

Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients (APIs), advanced intermediates and related services for the pharmaceutical industry.

Our core business sectors include custom synthesis and Generic API manufacturing.
The manufacturing site is located in Cameri, Italy. This 110,000 sq. meter, cutting-edge multipurpose plant, fully designed under cGMP compliance, has been successfully audited and approved by the main regulatory authorities including AIFA, FDA and PMDA.

We are a locally rooted company yet part of an international network, with commercial offices in key strategic geographies.